摘要
目的探讨创伤性颅脑损伤患者血清miR-422a,miR-212-5p表达与病情和预后的相关性,分析miR-422a,miR-212-5p诊断创伤性脑损伤患者预后的价值。方法连续性选择2018年4月~2020年6月山东省菏泽市中医院收治的173例创伤性颅脑损伤患者(创伤组)和同期125例志愿者(对照组)。根据格拉斯哥昏迷量表(GCS)评分将创伤组患者分为轻度组(GCS评分13~15分,57例),中度组(GCS评分9~12分,63例)和重度组(GCS评分3~8分,53例),追踪临床结局,根据格拉斯哥预后量表(GOS)评分将患者分为预后不良组(GOS评分1~3分,62例)和预后良好组(GOS评分4~5分,111例)。检测所有受试者血清miR-422a,miR-212-5p表达,比较组间差异,分析miR-422a,miR-212-5p与创伤性颅脑损伤患者预后的关系以及miR-422a,miR-212-5p预测患者预后的价值。结果创伤组血清miR-422a表达高于对照组(3.02±1.02 vs 0.95±0.21),miR-212-5p表达低于对照组(1.03±0.28 vs 2.85±0.61),差异均有统计学意义(t=22.340,34.544,均P<0.05)。重度组血清miR-422a表达高于中度组和轻度组(4.01±0.13 vs 2.92±0.66,2.21±0.12;t=11.824,75.516,均P<0.05),miR-212-5p表达低于中度组和轻度组(0.84±0.06 vs 0.97±0.25,1.27±0.04;t=3.695,44.512,均P<0.05),预后不良组血清miR-422a表达高于预后良好组(4.05±0.11 vs 2.44±0.31,t=22.340,P<0.05),miR-212-5p表达低于预后良好组(0.83±0.06 vs 1.14±0.21,t=22.340,P<0.05),差异均有统计学意义。低GCS评分(OR=0.825,95%CI:0.721~0.945),高miR-422a表达(OR=1.394,95%CI:1.194~1.627),低miR-212-5p表达(OR=0.744,95%CI:0.667~0.831)是创伤性颅脑损伤患者预后不良的危险因素(均P<0.05)。联合miR-422a,miR-212-5p预测创伤性颅脑损伤患者预后不良的曲线下面积为0.907,高于单独检测miR-422a,miR-212-5p的0.797,0.775(Z=2.412,2.561,均P<0.05)。结论miR-422a过表达和miR-212-5p表达缺失与创伤性脑损伤严重程度和不良预后有关,可作为预后预测的潜在生物学指标。
Objective To investigate the correlation between the expression of serum miR-422a and miR-212-5p in patients with traumatic brain injury with the condition and prognosis,and analyze the diagnostic value of miR-422a and miR-212-5p in the prognosis of patients with traumatic brain injury.Methods A total of 173 patients with traumatic craniocerebral injury(trauma group)and 125 volunteers(control group)admitted to Heze Hospital of Traditional Chinese Medicine of Shandong Province from April 2018 to June 2020 were successively selected.According to the Glasgow Coma Scale(GCS)score,the patients in the trauma group were divided into mild group(GCS score 13~15,57 cases),moderate group(GCS score 9~12,63 cases)and severe group(GCS score 3~8,53 cases).The clinical outcome was tracked,according to Glasgow Outcome Scale(GOS),the patients were divided into poor prognosis group(GOS score 1~3,62 cases)and good prognosis group(GOS score 4~5,111 cases).The expression of serum miR-422a and miR-212-5p of all subjects was detected,and the differences between groups were compared to analyze the relationship between miR-422a and miR-212-5p and the prognosis of patients with traumatic brain injury,as well as the value of miR-422a and miR-212-5p in predicting the prognosis of patients.Results The expression of miR-422a in the trauma group was higher than that in the control group(3.02±1.02 vs 0.95±0.21),and the expression of miR-212-5p in the trauma group was lower than that in the control group(1.03±0.28 vs 2.85±0.61),the difference sentences were statistically significant(t=22.340,34.544,all P<0.05).The expression of miR-422a in the severe group was higher than that in the moderate and mild groups(4.01±0.13 vs 2.92±0.66,2.21±0.12;t=11.824,75.516,all P<0.05),and the expression of miR-212-5p was lower than that in the moderate and mild groups(0.84±0.06 vs 0.97±0.25,1.27±0.04;t=3.695,44.512,P<0.05).The expression of miR-422a in the poor prognosis group was higher than that in the good prognosis group(4.05±0.11 vs 2.44±0.31,t=22.340,P<0.05),and the expression of miR-212-5p was lower than that in the good prognosis group(0.83±0.06 vs 1.14±0.21,t=22.340,P<0.05),the difference sentences were statistically significant,respectively.Low GCS score(OR=0.825,95%CI:0.721~0.945),high miR-422a expression(OR=1.394,95%CI:1.194~1.627),low miR-212-5p expression(OR=0.744,95%CI:0.667~0.831)was risk factors for poor prognosis in patients with traumatic brain injury(P<0.05).The area under the curve of combined miR-422a and miR-212-5p for predicting poor prognosis in patients with traumatic brain injury was 0.907,which was higher than 0.797 and 0.775 of miR-422a and miR-212-5p alone(Z=2.412,2.561,all P<0.05).Conclusion Overexpression of miR-422a and deletion of miR-212-5p were associated with severity and poor prognosis of traumatic brain injury,and can be used as a potential biological indicator for prognosis prediction.
作者
赵大龙
田金灵
ZHAO Da-long;TIAN Jin-ling(Department of Laboratory Medicine,Hospital of Traditional Chinese Medicine of Heze City,Shandong Heze 274000,China)
出处
《现代检验医学杂志》
CAS
2022年第1期67-71,共5页
Journal of Modern Laboratory Medicine
